Table 1

Anthropometric and fasting metabolic characteristics of the VALOBAB-C study population at screening

Control3 g-PL5 g-PLHealthy range/value
(n=19)(n=19)(n=20)
Age (years)58±260±258±1
Body weight (kg)78.5±2.575.3±1.975.6±1.1
BMI (kg/m²)30.5±0.829.3±0.629.3±0.520–25*
Waist circumference (cm)96.5±2.497.0±1.597.9±1.4≤80†
Hip circumference (cm)110.4±1.7106.9±1.8106.5±1.7
Waist/hip circumference ratio0.87±0.020.91±0.010.92±0.01≤0.85*
Systolic BP (mm Hg)132.1±2.9129.2±3.1133.7±2.6<130†
Diastolic BP (mm Hg)79.8±1.682.0±1.480.5±1.8<85†
Total C (mmol/L)6.0±0.25.7±0.25.8±0.2<5.2‡
LDL-C (mmol/L)3.9±0.23.7±0.23.8±0.2≤3.3‡
HDL-C (mmol/L)1.3±0.01.4±0.01.3±0.0>1.3†
TAG (mmol/L)1.6±0.11.4±0.21.4±0.1<1.7†
Glucose (mmol/L)4.9±0.14.9±0.14.7±0.1<5.6†
CRP (mg/L)5.3±1.05.3±1.13.7±0.6<1–3§
AST (IU/L)21.9±1.025.2±2.124.2±1.7<34¶
ALT (IU/L)27.5±2.429.2±3.130.6±3.1<55¶
  • Data are presented as mean±SEM. Subjects were randomised therefore no statistical analysis was performed on subject characteristics at screening.

  • *According to WHO.66

  • †Based on the International Diabetes Federation metabolic syndrome worldwide definition.67

  • ‡According to the National Cholesterol Education Program Adult Treatment Panel III.68

  • §Recommendations of the American Heart Association and Centers for Disease Control and Prevention established levels of cardiovascular risk by assigning CRP values as follows: low risk: <1.0 mg/L; average risk: 1.0–3.0 mg/L; high risk: >3.0 mg/L.31

  • ¶According to reference ranges provided by the hospital laboratory in charge of the measurement of transaminases.

  • ALT, alanine amino transferase; AST, alanine aspartate transferase; BP, blood pressure; BMI, body mass index; C, cholesterol; CRP, C reactive protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PL, polar lipids, TAG, triacylglycerol.